搜索到 1000 条关于 카지노 룰렛 Zx444.top 코드 6520 바카라 승리 카지노 총판구인 카지노쿠폰 주는 곳 sA 的文章
-
-
2014.11.07 盘点:2014上半年制药行业十大并购交易
雀巢皮肤健康(Nestlé Skin Health SA)的子公司。其中包括高德美的痤疮和银屑病药物,以及雀巢公司原有的皮肤科处方药、非处方药
-
-
2013.10.30 免疫组库测序产品技术说明文档
and Molecular Immunology. 5th edition. Saunders, Philadelphia.4.Frank SA (2002
-
-
2013.01.27 阻塞性睡眠呼吸暂停低通气综合征患者夜间多尿发病机制的研究进展
OSAHS和夜间多尿的定义OSAHS是指睡眠过程中上气道塌陷阻塞引起的呼吸暂停和通气不足、伴有打鼾、睡眠结构紊乱、频繁发生血氧饱和度(Sa02)下降
-
-
2013.01.22 医学界最具变革潜力的六大趋势
。现在,这些孩子都十几岁了,而如果不接受治疗,他们可能不到十岁就会离开人世。另一些公司也在推动基因治疗。诺华制药(Novartis SA)正与
-
2011.11.15 术后肺水肿一例
:EVLW={(SA×Lp)〔(Pmv-Ppmv)-σ(πmv-πpmv)〕}-Flymph也许战友看漏了原文
-
2008.11.11 血栓形成机制及治疗进展
, Birktoft JJ, Steer SA,et al. Structure and biology of tissuefactor pathway inhibitor
-
2006.12.12 非酒精性脂肪性肝病诊疗指南
comorbidities. Semin Liver Dis, 2004, 24: 389-397.14 Harrison SA, Torgerson S, Hayashi P
-
2012.09.19 2011年生物仿制药会议(Biosimilars Asia 2011)
时间: 2011-5-23 至 2011-5-26
地点:Grand Hyatt Shanghai
主办单位: IBC Asia (S) Pte Ltd会议简介
According to Business Insights, an estimated $25bn worth of biologics will lose patent protection by 2016, creating a significant market opportunity for biosimilars. However, the reality is that biosimilar development is a risk-fraught activity that demands significant resources in R&D, manufacturing expertise, regulatory know-how, clinical-trial capabilities, and a high level of financial investment.
Biosimilar development is riddled with complexities, ranging from regulatory, to manufacturing to marketing, and is one of the most expensive propositions in the pharmaceutical industry. It is estimated that it costs between US$100-200 million to bring a biosimilar product to market. With so much at stake, biosimilars represent not only substantial growth but equally risk..
IBC’s 2nd Annual Biosimilars Asia 2011 Summit is the ONLY conference in Asia catering to this region’s specific queries. With unprecedented insights from leading innovators and biosimilar companies, you will network and learn how to strategically position your company to maximize your ROI. Biosimilars Asia 2011 is attended by key stakeholders in the region and beyond, enabling you to make informed strategic decisions.
5 Reasons To Attend - Only conference in Asia which addresses concerns faced by the Asian biosimilar companies with experts from the region and beyond
- Learn from and personally meet senior executives from the major stakeholders amongst from biosimilar to innovator companies
- The most comprehensive event highlighting key challenges in the industry including manufacturing, marketing, pricing, transitioning from generics to biosimilars and regulatory issues
- Showcasing unique case studies from leading Asian and international biosimilar companies
- Gather the latest insights from regional biosimilar companies and MNCs about their strategic decisions and how they are positioning themselves for success
Industry Gurus / Speakers Biocon, Pfizer, Genentech, Roche, Teva, Hospira, Sandoz, Momenta, Intas, Dr Reddy’s, Shenzhen Main Luck Pharmaceuticals Past Attendees Include Vice President, ASTRAZENECA INNOVATION CENTER (China)
Senior Director, GENENTECH INC, (USA)
Managing Director, BECTON DICKINSON CO (BD BIOSCIENCES) (Singapore)
Managing Director, ASAHI GLASS CO LTD (Japan)
Deputy General Manager, SINOPHARM (China)
Head, Biotech Research, USV LTD (India)
General Manager, JCR PHARMACEUTICALS CO LTD (Japan)
Vice President, R&D/Business Development, MAIN LUCK PHARMACEUTICALS INC (China)
Senior Research Associate, HANWHA CHEMICAL (South Korea)
Vice President, BOEHRINGER INGELHEIM GMBH (Germany)
General Manager, GLAXOSMITHKLINE (CHINA) INVESTMENT CO LTD (China)
IP Director, HOSPIRA (AUSTRALIA)
President, MYCENAX BIOTECH INC (Taiwan)
Senior Director, MERCK & CO INC (USA)
Associate Director, DR REDDY''''''''S LABORATORIES LTD (India)
Chairman, SHENZHEN SCIPROGEN BIO-PHARMACEUTICAL CO LTD (SCIPROGEN) (China)COO, SHANGHAI CELGEN BIOPHARMACEUTICALS (China)
Chief Representative, TTY BIOPHARM CO LTD (Taiwan)COO, 3SBIO (China)
Project Director, JIANGSU CHIA TAI TIANQING PHARMACEUTICAL CO LTD (China)Associate Director, PFIZER INVESTMENT CO LTD (China)
General Manager, NIPPON KAYAKU CO LTD (Japan)
President, HENLIUS BIOPHARMACEUTICALS INC & SHANGHAI HENLIUS BIOTECH (USA)
Vice President, RANBAXY (USA)Registration FEES per delegate Early Bird Rate
Register & Pay before 11 March 2011Special Rate
Register & Pay before 15 April 2011Normal Rate
Register & Pay after 15 April 2011Group Rate
Group of 3 or more? US$ / CNYUS$ / CNYUS$ / CNYUS$ / CNY4 day package
(Conf + Pre & Post Workshops)2,495 /
16,6002,695 /
17,9502,895 /
19,5002,175 /
14,6503.5 day package (Conf + Workshop C & A or B ) 2,295 /
15,5002,495 /
16,6002,695 /
17,9502,025 /
13,5003 day package (Conf + Workshop A & B or C) 1,995 /
13,5002,195 /
14,6002,395 /
15,9501,795 /
12,0002.5 day package (Conf + Workshop A or B) 1,795 /
12,0001,995 /
13,5002,195 /
14,6001,695 /
10,9502 day package
(Conf only)1,495 /
9,9501,695 /
11,3001,895 /
12,6001,495 /
9,950PAYMENT TERMS
Payment must be received 10 business days prior to the event. To take advantage of discounts with an expiry cut-off date, registration and payment must be received by the cut off date.Payments by Singapore Dollars (S$)
Payments by RMB (CNY)- Payments by S$ bank draft or cheque should be made in favour of “IBC Asia (S) Pte Ltd” payable in Singapore.
- Payment by telegraphic transfer in S$ must be made to:
IBC Asia (S) Pte Ltd
A/C No.: 147-059513-001 (SGD)
The Hongkong and Shanghai Banking Corporation Limited
21 Collyer Quay, HSBC Building, Singapore 049320
Bank Swift Code: HSBCSGSG
Bank Code: 7232 - Payment by Credit Card (AMEX, VISA or MASTERCARD). Please provide your Card Number, Name of Cardholder, Expiry Date and your Signature and send it by fax to +65 6508 2407.
- Payment by telegraphic transfer in CNY must be made to:
A/C Name:
A/C No.: 720-031103-001
Beneficiary Bank:
Bank Address: No. 1000 Lujiazui Rind Road,
Pudong, Shanghai 200120, P.R. China
Bank Swift Code: HSBCCNSH
Should you be unable to attend, a substitute delegate is welcome at no extra charge. Cancellations must be received in writing at least 10 business days before the start of the event, to receive a refund less 10% processing fee per registration. The company regrets that no refund will be made available for cancellation notifications received less than 10 business days before the event.IMPORTANT NOTE:
Please quote the name of the delegate, event title and invoice number on the advice when remitting payment. Bank charges are to be deducted from participating organisations own accounts. Please fax your payment details (copy of remittance advice, cheque or draft to +65 6508 2407.
Attendance will only be permitted upon receipt of full payment. Participants wishing to register at the door are responsible to ensure all details are as published. IBC Asia will not be responsible for any event re-scheduled or cancelled.
DATA PROTECTION
The personal information entered during your registration/order, or provided by you, will be held on a database and may be shared with companies in the Informa Group in the UK and internationally. Sometimes your details may be obtained from or shared with external companies for marketing purposes. If you do not wish your details to be used for this purpose, please contact Winnie Seah (Database) on winnie.seah@ibcasia.com.sg Tel: +65 6508 2468 or Fax: +65 6508 2408.联系方式电话:+65 650 82401
-
2012.09.19 2010 第五届国际基因组学大会(ICG-V)
, please click: http://www.genomeconference.org/pages/Abstract.aspxTop Poster
-
2012.09.19 2012 中国医疗器械高峰论坛
trials and regulatory affairs A special showcase of top 10 Chinese innovative device companies and top 5 selected US/EU device companies interested in China
-
2024.04.03 211 教授,当选院士
青岛农业大学植物医学学院院长;2022 年到贵州大学农学院工作。在昆虫学顶尖杂志累计发表论文 444 余篇,SCI 论文 330 多篇,文章被引 13,900 余
-
-
2017.07.27 VTE 患者隐源性肿瘤风险评分有助识别肿瘤高风险患者
符合入选标准,444 例被确诊为隐源性肿瘤。以男性,年龄>70 岁,慢性肺疾病、贫血、血小板计数升高 (≧350000x1000/mm3),既往 VTE
-
-
2012.10.15 Qualitest公司召回氨酚氢可酮
了C1440512A批号的药品消费者应打1-800-444-4011联系Qualitest公司。消费者如果不能确定是否购买使用过该批次 的药品,应咨询药店或保健专业人员。药剂师
-
-
2012.10.15 Qualitest公司召回氨酚氢可酮
了C1440512A批号的药品消费者应打1-800-444-4011联系Qualitest公司。消费者如果不能确定是否购买使用过该批次 的药品,应咨询药店或保健专业人员。药剂师
-
-
2012.10.15 Qualitest公司由于药物成分超标召回氨酚氢可酮
了C1440512A批号的药品消费者应打1-800-444-4011联系Qualitest公司。消费者如果不能确定是否购买使用过该批次的药品,应咨询药店或保健专业
-
-
2012.09.30 儿科心脏手术后的严格血糖控制不能降低死亡率
受试儿童中共有444例 (91%)接受胰岛素治疗,而标准治疗组的490例儿童则仅有9例(2%)。虽然与标准治疗组相比,严格血糖控制组患者更早(6小时VS 16
-
2011.08.15 家中多次测血压取均值最准确
-788.)。上述结果来自对高血压干预远程医疗研究(HINTS)数据的二次分析。该研究共纳入444名血压控制不佳的退伍军人,随访18个月。采用3种方法
-
2020.06.17 【直播 | 现场】计算机辅助设计—分子模拟与蛋白互作研讨班(8.20-22)
。【报名回执】访问此链接填写报名回执(https://www.wjx.top/jq/80710449.aspx)【咨询请联系】QQ 号:2814500767邮箱
-
-
2017.08.13 卒中后抗血小板出血风险有多大?有这10个特征需谨慎
)(即 S2TOP-BLEED 评分模型,见表1)。表 1 预测严重出血的S2TOP-BLEED 评分(来自多变量 Cox 回归模型)具体评分方法为,根据患者临床特征评估 S2TOP-BLEED 评分列表中每一栏分值,除了年龄相关的项目外,将其他所有项目分值想加得总分,再将总分代入图 1 所示风险分布图中,得到不同
-
-
2014.12.23 远程协作治疗创伤后应激障碍
明,使用远程医疗工具,如电话,互动视频和共享电子病历进行的多学科PTSD非现场干预,即创伤后应激障碍远程医疗服务(TOP)与常规护理(UC)相比,治疗效果显著提升...包括了2009年11月至2011年9月份在CBOCs接受治疗的265名主要生活在农村的退伍军人。所有患者均符合PTSD诊断标准,他们被随机分配接受TOP治疗(N